Crystalline Forms of Quinazolinyl-Benzonitrile Compound and Ocular Formulations
Summary
USPTO granted patent US12600702B2 to Bausch + Lomb Ireland Limited for crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof. The patent covers methods for treating ocular surface pain, dry eye disease, and ocular hyperemia. The application was filed on February 13, 2020 under application number 17430819, with 16 claims granted.
What changed
USPTO granted patent US12600702B2 to Bausch + Lomb Ireland Limited for crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and formulations thereof. The patent covers methods for treating ocular surface pain, dry eye disease, and ocular hyperemia. The filing date was February 13, 2020, with the patent issuing April 14, 2026.
Competitors developing similar ocular therapeutics containing this quinazolinyl-benzonitrile compound should review the 16 granted claims for potential infringement concerns. The patent holder gains exclusive rights to manufacture, use, and commercialize these crystalline forms and their ocular formulations through approximately 2040.
What to do next
- Monitor patent portfolio for potential licensing opportunities
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
Grant US12600702B2 Kind: B2 Apr 14, 2026
Assignee
Bausch + Lomb Ireland Limited
Inventors
Joseph Paul Bullock, Chinmay Maheshwari, Quintus Medley, Muneto Mogi, Michela Montecchi-Palmer, Gregory Morandi, Michael Mutz, Kalliopi Stasi, Christopher Stephen Towler
Abstract
The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
CPC Classifications
C07D 239/91 A61P 27/02 C07B 2200/13
Filing Date
2020-02-13
Application No.
17430819
Claims
16
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.